399 reports of this reaction
1.4% of all LOPINAVIR AND RITONAVIR reports
#19 most reported adverse reaction
OSTEOPOROSIS is the #19 most commonly reported adverse reaction for LOPINAVIR AND RITONAVIR, manufactured by AbbVie Inc.. There are 399 FDA adverse event reports linking LOPINAVIR AND RITONAVIR to OSTEOPOROSIS. This represents approximately 1.4% of all 28,252 adverse event reports for this drug.
Patients taking LOPINAVIR AND RITONAVIR who experience osteoporosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OSTEOPOROSIS is a less commonly reported adverse event for LOPINAVIR AND RITONAVIR, but still significant enough to appear in the safety profile.
In addition to osteoporosis, the following adverse reactions have been reported for LOPINAVIR AND RITONAVIR:
The following drugs have also been linked to osteoporosis in FDA adverse event reports:
OSTEOPOROSIS has been reported as an adverse event in 399 FDA reports for LOPINAVIR AND RITONAVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
OSTEOPOROSIS accounts for approximately 1.4% of all adverse event reports for LOPINAVIR AND RITONAVIR, making it a notable side effect.
If you experience osteoporosis while taking LOPINAVIR AND RITONAVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.